<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>NMS:SRPT on 无关紧要的宇宙</title><link>https://316140221.github.io/Hugo/zh/tags/nmssrpt/</link><description>Recent content in NMS:SRPT on 无关紧要的宇宙</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Mon, 21 Jul 2025 15:12:05 +0800</lastBuildDate><atom:link href="https://316140221.github.io/Hugo/zh/tags/nmssrpt/index.xml" rel="self" type="application/rss+xml"/><item><title>Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-21-sarepta-worth-0-amid-unwinnable-fda-fight-analyst-/</link><pubDate>Mon, 21 Jul 2025 15:12:05 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-21-sarepta-worth-0-amid-unwinnable-fda-fight-analyst-/</guid><description>Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, accord</description></item><item><title>Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-21-sarepta-worth-0-amid-unwinnable-fda-fight-analyst-/</link><pubDate>Mon, 21 Jul 2025 15:12:05 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-21-sarepta-worth-0-amid-unwinnable-fda-fight-analyst-/</guid><description>Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, accord</description></item></channel></rss>